The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases

Purpose of investigation: The objective of this retrospective multicenter study was to assess the prognostic relevance of histologic type in uterine sarcomas.

Methods: The hospital reports of 249 patients with uterine sarcomas were reviewed. Surgery was the initial therapy for all patients. Histologic type was leiomyosarcoma in 95 cases, low-grade endometrial stromal sarcoma (ESS) in 19, high-grade ESS in 34, and carcinosarcoma in 101. Postoperative treatment was given without well-defined protocols. Median follow-up of survivors was 97 months.

Results: In the whole series 2-year, 5-year, and 10-year survival rates were 53.5%, 41.6%, and 35.8%, respectively, and median survival was 31 months. At univariate analysis survival was significantly related to stage (p = 0.0001), mitotic count (p = 0.0001), and histologic type (low-grade ESS vs leiomyosarcoma vs carcinosarcoma vs high-grade ESS, median: not reached vs 27 months vs 21 months vs 16.5 months, p = 0.0011), but not to postoperative therapy and patient age. The Cox model revealed that tumor stage, mitotic count and histologic type were independent prognostic variables for survival. In detail, the risk of death was significantly lower for low-grade ESS (risk ratio [RR] = 0.257; 95% confidence interval [CI] = 0.071-0.931) and carcinosarcoma (RR = 0.509; 955 CI = 0.324-0.799) when compared to leiomyosarcoma. Conversely, no significant difference in survival was found between leiomyosarcoma and high-grade ESS.

Conclusions: Histologic type is an independent prognostic variable for survival in uterine sarcomas. Low-grade ESS has the best clinical outcome, whereas leiomyosarcoma has the poorest one. It is noteworthy that, when adjusting for stage and mitotic count, leiomyosarcoma has a significantly worse prognosis than carcinosarcoma.

Uterine sarcoma; Leiomyosarcoma; Low-grade endometrial stromal sarcoma; High-grade endometrial stromal sarcoma; Carcinosarcoma; Prognosis

[1] Salazar O. M., Bonfiglio T. A., Patten S. F., Keller B. E., Feldstein M., Dunne M. E., Rudolph J.: "Uterine sarcomas. Natural history, treatment and prognosis". Cancer, 1978, 42, 1152.

[2] Salazar O. M., Bonfiglio T. A., Patten S. F., Keller B. E., Feldstein M. L., Dunne M. E., Rudolph J. H.: "Uterine sarcomas. Analysis of failures with special emphasis on the use of adjuvant radiation therapy". Cancer, 1978, 42, 1161.

[3] W heelock J. B., Krebs H. B., Schneider V., Goplerud D. R.: "Uterine sarcoma: Analysis of prognostic variables in 71 cases". Am. J. Obstet. Gynecol., 1985, 151, 1016.

[4] Covens A. L., Nisker J. A., Chapman W. B., Allen H. H.: "Uterine sarcoma: An analysis of 74 cases". Am. J. Obstet. Gynecol., 1987, 156, 370.

[5] Kempson R. L., Bari W.: "Uterine sarcomas. Classification, diagnosis, and prognosis". Hum. Pathol., 1970, 1, 331.

[6] Harlow B. L., Weiss N. S., Lofton S.: "The epidemiology of sarcomas of the uterus". J. Natl. Cancer Inst., 1986, 76, 399.

[7] Norris H.J., Taylor H. B.: "Mesenchymal tumors of the uterus.I. A clinical and pathological study of 53 endometrial stromal tumors. Cancer, 1966, 19, 755.

[8] Yoonessi M., Hart W. R.: "Endometrial stromal sarcomas". Cancer, 1977, 40, 898.

[9] Piver M. S., Rutledge F. N., Copeland L., Webster K., Blumenson L., Suh O.: "Uterine endolymphatic stromal myosis: A collaborative study". Obstet. Gynecol., 1984, 64, 173.

[10] De Fusco P.A., Gaffey T. A., Malkasian G.D. jr, Long H.J., Cha S. S.: "Endometrial stromal sarcoma: Review of Mayo Clinic experience, 1945-1980". Gynecol. Oncol., 1989, 35, 8.

[11] Taina E., Maenpaa J., Erkkola R., Ikkala J., Soderstrom O., Viitanen A.: "Endometrial stromal sarcoma: A report of nine cases". Gynecol. Onco/., 1989, 32, 156.

[12] Evans H. L.: "Endometrial stromal sarcoma and poorly differentiated endometrial sarcoma". Cancer, 1982, 50, 2170.

[13] Mansi J. L., Ramachandra S., Wiltshaw E., Fisher C.: "Endometrial stromal sarcomas". Gynecol. Oncol., 1990, 36, 113.

[14] Salazar 0. M.,D unne M. E.: "The role of radiation therapy in the management of uterine sarcomas". Int. J. Radiat. Oncol. Biol. Phys., 1980, 6, 899.

[15] Kahanpaa K. V., Wahlstrom T., Grahn P., Heinonen E., Nieminen U., Widholm 0.: "Sarcomas of the uterus: A clinicopathologic study of 119 patients". Obstet. Gynecol., 1986, 67, 417.

[16] George M., Pejovic M. H., Kramar A. and Gynecologic Cooperating Group of French Oncology Centers: "Uterine sarcomas: Prognostic factors and treatment modalities - Study on 209 patients". Gynecol. Oncol., 1986, 24, 58.

[17] Echt G., Jepson J., Steel J., Langholz B., Luxton G., Hernandez W., Astrahan M., Petrovich Z.: "Treatment of uterine sarcomas". Cancer, 1990, 66, 35.

[18] Malmstrom H., Schmidt H., Persson P. G., Carstensen J., Nordenskjold B., Simonsen E.: "Flow-cytometric analysis of uterine sarcoma: Ploidy and S-phase rate as prognostic indicators". Gynecol. Oncol., 1992, 44, 172.

[19] Olah K. S., Dunn J. A., Gee H.: "Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: The result of a retrospective study of 423 cases of uterine sarcoma". Br. J. Obstet. Gynaecol., 1992, 99, 590.

[20] Wolfson A. H., Wolfson D. J., Sittler S. Y., Breton L., Markoe A. M., Schwade J. G. et al.: "A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas". Gynecol. Oncol., 1994, 52, 56.

[21] Gadducci A., Landoni F., Sartori E., Zola P., Maggino T., Lissoni A. et al.: "Uterine leiomyosarcoma: Analysis of treatment failures and survival". Gynecol. Oncol., 1996, 62, 25.

[22] Gadducci A., Sartori E., Landoni F., Zola P., Maggino T., Urgesi A. et al.: "Endometrial stromal sarcoma: Analysis of treatment failures and survival". Gynecol. Oncol., 1996, 63, 247.

[23] Sartori E., Bazzurini L., Gadducci A., Landoni F., Lissoni A., Maggino T. et al.: "Carcinosarcoma of the uterus: A clinicopathological multicenter CTF study". Gynecol. Oncol., 1997, 67, 70.

[24] Berchuck A., Rubin S. C., Hoskins W. J., Saigo P. E., Pierce V. K., Lewis J. L. Jr.: "Treatment of uterine leiomyosarcoma". Obstet. Gynecol., 1988, 71, 845.

[25] Nielsen S. N., Podratz K. C., Scheithauer B. W., O'Brien P. C.: "Clinicopathologic analysis of uterine malignant mixed mullerian tumors". Gynecol. Oncol. 1989, 34, 372.

[26] Larson B., Silfversward C., Nilsson B., Pettersson F.: "Mixed mu!lerian tumours of the uterus prognostic factors: A clinical and histopathologic study of 147 cases". Radiother. Oncol., 1990, 17, 123.

[27] Ali S., Wells M.: "Mixed mullerian tumors of the uterine corpus: A review". Int. J. Gyneco/. Cancer, 1993, 3, 1.

[28] Major F. J., Blessing J. A., Silverberg S. G., Morrow C. P., Creasman W. T., Currie J. L. et al.: "Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study". Cancer, 1993, 71 (4 Suppl), 1702.

[29] Silverberg S. G., Major F. J., Blessing J. A., Fetter B., Askin F. B., Liao S. Y., Miller A.: "Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases". Int. J. Gynecol. Pathol., 1990, 9, I.

[30] Zelmanowicz A., Hildesheim A., Sherman M. E., Sturgeon S. R., Kurman R. J., Barret R. J. et al.: "Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors". Gynecol. Oncol., 1998, 69, 253.

[31] Thigpen J. T., Blessing J. A., Orr J. W. Jr,D i Saia P. J.: "Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: A Gynecologic Oncology Group study". Cancer Treat. Rep., 1986, 70, 271.

[32] Jansen R. L., van der Burg M. E., Verweij J., Stoter G.: "Cyclophosphamide, hexamethylmelamine, adriamycin and cisplatin combination chemotherapy in mixed m esodermal sarcoma of the female genital tract". Eur. J. Cancer Clin. Oncol., 1987, 23, 1131.

[33] Peters W. A. III, Rivkin S. E., Smith M. R., Tesh D. E.: "Cisplatin and adriamycin combination chemotherapy for uterine stromal sarcomas and mixed mesodermal tumors". Gynecol. Oncol., 1989, 34, 323.

[34] Plaxe S. C., Dottino P. R.,G oodman H. M.,D eligdisch L., Idelson M., Cohen C. J.: "Clinical features of advanced ovarian mixed mesoderrnal tumors and treatment with doxorubicin- and cis-platinum-based chemotherapy". Gynecol. Oncol., 1990, 37, 244.

[35] Thigpen J. T., Blessing J. A., Beecham J., Homesley H., Yordan E.: "Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: A Gynecologic Oncology Group study". J. Clin. Oncol., 1991, 9, 1962.

[36] Baker T. R., Piver M. S., Caglar H., Piedmonte M.: "Prospective trial of cisplatin, adriamycin, and dacarbazine in metastatic mixed mesodermal sarcomas of the uterus and ovary". Am. J. Clin. Oncol.,1 991,14, 246.

[37] BerchuckA., Rubin S. C., Hoskins W. J., Saigo P. E., Pierce V. K., Lewis J. L. Jr.: "Treatment of endometrial stromal tumors". Gynecol. Oncol., 1990, 36, 60.

[38] Styron S. L., Burke T. W., Linville W. K.: "Low-grade endometrial stromal sarcoma recurring over three decades". Gynecol. Oncol., 1989, 35, 275.